EVALUATING SERUM C-REACTIVE PROTEIN LEVEL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE – A CROSS-SECTIONAL STUDY

1Dr. Karthika. M, 2Dr. Prakash Chandra Bhardwaj, 3Dr.Laimayum Amarnath Sharma, 4Dr. W Kanan, 5Dr. W Asoka Singh

1Senior Resident, Department of Physiology, JIPMER, Puducherry, India.  
2MD (Physiology), Department of Health Services, Manipur, India.  
3Medical Officer, DR TB Center, JNIMS Hospital, Imphal, Manipur, India.  
4Professor & Head Department of Physiology, Regional Institute of Medical Sciences, Imphal, Manipur, India.  
5Professor Department of Respiratory Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India.

Abstract

Patients with the chronic obstructive pulmonary disease have an ongoing systemic inflammation, which can be assessed by measuring serum C-reactive protein. Objective: To explore whether CRP could be used as an independent predictor of disease outcome in COPD. Methods: A cross-sectional study was conducted among 50 COPD patients attending Respiratory Medicine outpatient services in Regional Institute of Medical Sciences (RIMS), Imphal from January 2015 to September 2016. Patients aged 18-67 were included in the study after obtaining Ethical approval from the Research Ethics Board, RIMS, Imphal. Computerized Spirometer Helios 401 was the instrument used to measure lung volumes and capacities. BeneSphera™ CRP Latex slide test kit was used to estimate serum c-reactive protein. Results: The present study was conducted on fifty COPD patients in which serum CRP level showed positive correlation with COPD (p=0.002) but serum CRP level with spirometric parameters showed significant negative correlation; FEV1 (r=0.451, p=0.001), FEV1/FVC (r=-0.617, p<0.001) and PEFR (r=-0.398, p=0.004). Conclusion: In our study we found an association between serum CRP level and severity of COPD and Plasma CRP may be used as a marker of prognosis in COPD as small increase is associated with poorer prognosis in COPD.

Keywords: CRP; Chronic obstructive pulmonary disease (COPD); Imphal.

Introduction

Obstructive airways disease is a group of condition distinguished by increased resistance and obstruction in the air passages, especially during expiration. The term OAD includes bronchial asthma; chronic obstructive pulmonary disease, consisting of chronic bronchitis and emphysema; bronchiectasis; cystic fibrosis and bronchiolitis [1].

COPD is a disease state characterized by airflow limitation that is not fully reversible. The airflow obstruction is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gas. There are around 50 million patients with COPD in India and COPD is the second leading cause of death in India. An estimate suggests that COPD will rise from the sixth to the third most common cause of death worldwide by 2020 [2].

Diagnosis of OAD is based on the patient’s history, signs, and symptoms, and on the results of spirometry and other pulmonary function tests. Spirometry assesses the obstruction of expiratory airflow, which is the characteristic functional defect in OAD. Spirometry is the most effective way of determining the severity of obstructive airway diseases [3].

C-reactive protein was first isolated in 1930 from the plasma of patients with pneumococcal pneumonia, CRP was so named because it binds to the C-polysaccharide of the pneumococcus. Modern molecular studies have determined that CRP is a member of the pentraxin family of proteins. It comprises five protomers, each of 206 amino acids, molecular weight 23 kDa, arranged in cyclic symmetry. With the participation of Ca²⁺ ions, it binds various proteins and phospholipids, particularly phosphocholine. It opsonizes particles and also activates complement via the classical pathway, but its actual biological function is unknown [4].

In the lungs, CRP has a protective function by acting against bacteria and apoptotic cells. Activated epithelial cells, alveolar macrophages and other inflammatory cells in COPD release IL-6 into the circulation. CRP is primarily produced by hepatocytes in response to IL-6 stimulation [5]. This stimulates an acute-phase response and increases the level of plasma CRP. C-reactive protein appears in blood in the acute stages of various inflammatory disorders but is undetectable in the blood of healthy persons [6].

Worldwide studies show that it has variable roles in COPD, some showing correlation with spirometric lung function while others show no significant relation. We would, therefore, like to explore its role in our study population and also try to explore whether it could become an independent predictor of disease outcome in COPD.

Materials and Methods

Study design: A cross-sectional study was conducted among 50 COPD patients attending Respiratory Medicine outpatient services in Regional Institute of Medical Sciences (RIMS), Imphal from January 2015 to September 2016. Patients aged 18-67 were included in the study after obtaining Ethical

Correspondence: Dr. Karthika. M, Senior Resident, Department of Physiology, JIPMER, Puducherry, India  
E-Mail: mkarthikambbs@gmail.com

© Authors; 2019. International Journal of Current Research in Physiology and Pharmacology; Sumathi Publications.  
This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited.  
(CC BY-NC-SA 4.0)
approval from the Research Ethics Board, RIMS, Imphal. The participants were recruited by Purposive sampling. Diagnosed COPD patients sent from Respiratory Medicine OPD, RIMS, Imphal were included in this study.

The patients with chronic disorders like hypertension, diabetes mellitus, cardiovascular diseases, bleeding disorders, inflammatory disorders, infection, malignancy and patients who had recent surgery were excluded from the study.

Computerized Spirometer Helios 401 of the Recorders and Medicare System, Chandigarh, India was the instrument used to measure lung volumes and capacities. The Helios software contains a set of prediction equations for computation of predicted parameter values.

The procedure was explained to the patient followed by a demonstration. The patient was asked to “take as deep a breath as possible” and then “blast as fast and hard as you can” and “keep blowing until I ask you to stop” preferably at least 3 seconds followed by a rapid inhalation (inspiration). A tight seal was ensured around the mouthpiece. During the test, a soft nose clip was used to prevent air from escaping through the nose. Coaching was active and vigorous; instructions were repeated as necessary. Three consecutive maneuvers were performed with a rest of 5 to 10 minutes between two maneuvers.

The best result among the three tests was recorded in the proforma. The results were compared with the predicted values for the same age, sex, height, and weight. Patients were classified on the basis of the GOLD Classification of COPD (2006)[7].

The study variables which include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), FEV1/FVC ratio, Forced Expiratory Flow during 25-75% of expiratory flow (FEF 25-75%), and Peak Expiratory Flow Rate (PEFR), were recorded by Helios Computerized Spirometer Model No. 401, in a sitting position. Spirometric values are better when done in a standing position but sitting posture is usually preferred when because of the risk of fall due to cough syncope when done in standing.

The study variables which include Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), FEV1/FVC ratio, Forced Expiratory Flow during 25-75% of expiratory flow (FEF 25-75%), and Peak Expiratory Flow Rate (PEFR), were recorded by Helios Computerized Spirometer Model No. 401, in a sitting position. Spirometric values are better when done in a standing position but sitting posture is usually preferred when because of the risk of fall due to cough syncope when done in standing.

| Spirometric parameters | Minimum Value (%pred) | Maximum Value (%pred) | Mean (%pred) | Standard Deviation |
|------------------------|-----------------------|-----------------------|--------------|--------------------|
| FVC                    | 36.00                 | 158.00                | 83.96        | 30.98              |
| FEV1                   | 9.00                  | 155.00                | 61.16        | 32.63              |
| FEV1/FVC               | 11.00                 | 111.00                | 71.06        | 20.25              |
| FEF 25-75%             | 6.00                  | 138.00                | 34.20        | 27.53              |
| PEFR                   | 6.00                  | 87.00                 | 34.70        | 19.70              |

Table 2. Association of the serum CRP level with the severity of COPD

| Severity of COPD | CRP | Total | p-value* |
|------------------|-----|-------|----------|
|                  | LESS THAN 6 mg/L | 6 mg/L | 12 mg/L |          |
| Normal           | 19  | 1     | 0        | 20       | 0.002    |
| Mild             | 1   | 2     | 0        | 3        |
| Moderate         | 5   | 3     | 3        | 11       |
| Severe           | 4   | 3     | 2        | 9        |
| Very severe      | 1   | 2     | 4        | 7        |
| Total            | 30  | 11    | 9        | 50       |

*Chi-Square Test
Table 1 shows the lung function test values of COPD patients as measured by a spirometer. FVC values were within normal limit. But the mean values of FEV₁, FEF₂⁵-⁷⁵% and PEFR were lower. The results suggest that in the COPD patients larger and smaller airways both were involved.

Above table shows the association between serum CRP level and severity of COPD. Total 9(18%) COPD patients had serum CRP level 12mg/L, in which 3(6%) patients belong to moderate category, 2(4%) patients belong to severe category, and 4(8%) patients belong to very severe category. And 11 (22%) COPD patients had serum CRP level 6mg/L, it included; 1(2%) patient with normal spirometry, 2(4%) patients were in mild category, 3(6%) patients were in each moderate and severe category, and 2(4%) patients were in very severe category (p=0.002).

Table 3. Correlation of different parameters of spirometry and age with serum CRP level in COPD patients (n=50)

| Variables | Correlation coefficient (r)* | p-value |
|-----------|-------------------------------|---------|
| FEV₁      | -0.451                        | 0.001   |
| FEV₁/FVC  | -0.617                        | <0.001  |
| PEFR      | -0.398                        | 0.004   |

*Pearson’s bivariate correlation coefficient

Table 3 shows that age, FEV₁, FEV₁/FVC, and PEFR were negatively correlated with serum C-reactive protein.

Discussion

COPD is the second leading cause of death in India and the disability from this disease is substantial and is expected to rise in India and worldwide. There are evidences pointing towards smoking being a risk factor COPD and for increased clinical symptoms and poorer lung function in COPD patients. Hence all possible efforts should be taken to make people quit smoking, by adopting more awareness and control programs. But smoking cessation is challenging so education advice, behavioral intervention along with drug therapy like nicotine replacement therapy with gums, patch or inhaler can be tried for better results.

The treatments available today have a minimum impact on the disease progression, so early diagnosis and treatment are necessary. Measures such as screening with spirometric tests in high-risk individuals especially the smokers in age group of 40-55 should be considered to reduce the mortality and morbidity due to COPD. In this study we were trying to find whether CRP levels can be used as a valid tool and an independent predictor of disease outcome in COPD so that it could be used to evaluate the clinical, prognostic and therapeutic outcomes.

The present study was conducted on fifty COPD patients in which serum CRP level showed positive correlation with COPD (p=0.002) but serum CRP level with spirometric parameters showed significant negative correlation; FEV₁ (r=-0.451, p=0.001), FEV₁/FVC (r=-0.617, p=0.000) and PEFR (r=-0.398, p=0.004).

There are evidences supporting our study from previous research work conducted by Moreton RE and Kennedy CR reported that CRP concentration in patients (age range 0.03-16.1 years, median: 6.7 years) with cystic fibrosis ranged from 0.01-304 mg/L while in healthy children ranged from 0.01-2.8 mg/L and correlation between CRP and FVC% predicted was significant (r=-0.781; p<0.001) [8].

Gan and colleagues aggregated data from five cross-sectional studies and estimated an average mean increase in serum CRP of 1.85 mg/L in individuals with stable COPD [9]. There were similar results in the study conducted by Fares M et al [10]. They showed that CRP level >1.1mg/L in infants with bronchiolitis. Hsieh MH et al [11] found a good correlation between serum hs-CRP and HRCT scores in the patients with stable non-cystic fibrosis bronchiectasis.

Similar results were shown in the study conducted by Tores et al [12] and Seemungal et al [13] the mean CRP level between the control group and COPD group were compared and was different by greater than 3.3 mg/L, which was found to be significant (P<0.001).

Conclusion

In this study, we were trying to find whether CRP proteins levels can be used as a valid tool in COPD patients so that it could be used to evaluate the clinical, prognostic and therapeutic outcomes. In our study we found association between serum CRP level and severity of COPD and Plasma CRP may be used as a marker of prognosis in COPD as small increase is associated with poorer prognosis in COPD.

Limitations

The serum CRP has been used for evaluation of COPD and other inflammatory conditions but several factors might affect serum levels of CRP. CRP may be elevated in obese individuals and also in people who have the habit of smoking. Ageing is also another confounding factor. Further longitudinal studies are necessary to evaluate whether CRP could be used as an independent predictor of disease outcome.

Ethical clearance: Ethical approval was obtained from the Research Ethics Board, RIMS, Imphal before the beginning of the study.

Source of funding: Self

Conflict of Interest: Nil

Acknowledgment

We acknowledge great help received from the scholars whose articles are cited and included in the references of this manuscript.

References

1. Weinberger SE, Rosen IM. Disturbances of respiratory function. In: Loscalzo J, editor. Harrison’s Pulmonary and Critical Care Medicine. New Delhi: McGraw-Hill; 2010. [Google Scholar]
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370(9589):765-73. [Google Scholar]
3. Bellamy D. Spirometry in practice: A practical guide to using spirometry in primary care. 2nd ed. London: BTS.
Karthika et al. Evaluating serum C-reactive protein level in patients with COPD.

COPD Consortium; 2005. [Google Scholar]

4 Block JL. Evaluation of cardiac injury and function. In: McPherson RA, Pincus MR, editors. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. New Delhi: Elsevier; 2009. [Google Scholar]

5 Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor β1, or platelet-derived growth factor B gene. Proc Natl Acad Sci USA 1995;92:9570. [Google Scholar]

6 Sonnenwirth AC. Serological tests in infectious disease-II. In: Sonnenwirth, Jarett L, editors. Gradwohl’s Clinical Laboratory Methods and Diagnosis. 8th ed. New Delhi: B.I. Publications Ltd; 1990. [Google Scholar]

7 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006). Available at: http://www.goldcopd.org. Accessed September 19, 2016.

8 Moreton RE, Kennedy CR. C reactive protein concentrations in cystic fibrosis. Arch Dis Child 1988;63:958-60. [Google Scholar]

9 Gan WQ, Man SFP, Senthilvelan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574. [Google Scholar]

10 Fares M, Mourad S, Rajab M, Rifai N. The use of C-reactive protein in predicting bacterial co-infection in children with bronchiolitis. N Am J MedSci 2011;3(3):152-6. [Google Scholar]

11 Hsieh MH, Fang YF, Chen GY, Chung FT, Liu YC, Wu CH, et al. The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis. Pulm Med 2013;2013(1):1-8. [Google Scholar]

12 Torres J. P. de, Cordoba-Lanus E., López-Aguilar C., Fuentes M, Muros de, Garcia A. Montejo de, Aguirre-Jaime A. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. The European Respiratory Journal 2006;27:902-7. [Google Scholar]

13 Seemungal T. A., Lun J. C., Davis G., Neblett C., Chinyepi N., Dookhan C.. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. International Journal of Chronic Obstructive Pulmonary Disease 2007;2:313-21. [Google Scholar]